Article
Two cases of proteasome inhibitors related thrombotic microangiopathies and literature review
2025-09-04
Abstract excerpt
<title>Abstract</title> <p> <bold>Background</bold> Multiple myeloma (MM) is a prevalent hematological malignancy, with proteasome inhibitors (PIs) playing a crucial role in its therapeutic management. Although PIs are generally well-tolerated and associated with relatively mild side effects, recent evidence has increasingly drawn attention to proteasome inhibitor-related thrombotic microangiopathy (PI-related...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 4e788c4a-6879-54fd-a1bf-79b9042155a3
- DOI
- 10.21203/rs.3.rs-7388047/v1
